HomeCompareOCSL vs BAX

OCSL vs BAX: Dividend Comparison 2026

OCSL yields 14.45% · BAX yields 2.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCSL wins by $70.85M in total portfolio value
10 years
OCSL
OCSL
● Live price
14.45%
Share price
$11.21
Annual div
$1.62
5Y div CAGR
52.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$70.87M
Annual income
$58,988,602.24
Full OCSL calculator →
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →

Portfolio growth — OCSL vs BAX

📍 OCSL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCSLBAX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCSL + BAX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCSL pays
BAX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCSL
Annual income on $10K today (after 15% tax)
$1,228.37/yr
After 10yr DRIP, annual income (after tax)
$50,140,311.90/yr
BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
At 15% tax rate, OCSL beats the other by $50,140,303.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCSL + BAX for your $10,000?

OCSL: 50%BAX: 50%
100% BAX50/50100% OCSL
Portfolio after 10yr
$35.45M
Annual income
$29,494,306.25/yr
Blended yield
83.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BAX right now

OCSL
Analyst Ratings
5
Buy
7
Hold
Consensus: Hold
Price Target
$12.00
+7.0% upside vs current
Range: $12.00 — $12.00
Altman Z
0.1
Piotroski
6/9
BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCSL buys
0
BAX buys
0
No recent congressional trades found for OCSL or BAX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCSLBAX
Forward yield14.45%2.28%
Annual dividend / share$1.62$0.36
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR52.4%-27%
Portfolio after 10y$70.87M$20.6K
Annual income after 10y$58,988,602.24$10.26
Total dividends collected$69.85M$602.00
Payment frequencyquarterlyquarterly
SectorBDCHealthcare
Analyst consensusHoldHold
Analyst price target$12.00$19.75

Year-by-year: OCSL vs BAX ($10,000, DRIP)

YearOCSL PortfolioOCSL Income/yrBAX PortfolioBAX Income/yrGap
1← crossover$12,902$2,202.39$10,866$166.33+$2.0KOCSL
2$17,853$4,047.30$11,750$123.31+$6.1KOCSL
3$27,079$7,976.36$12,664$90.97+$14.4KOCSL
4$46,206$17,231.74$13,617$66.89+$32.6KOCSL
5$91,320$41,879.29$14,619$49.07+$76.7KOCSL
6$215,599$117,886.96$15,679$35.94+$199.9KOCSL
7$627,105$396,413.81$16,802$26.30+$610.3KOCSL
8$2,313,266$1,642,263.98$17,998$19.23+$2.30MOCSL
9$11,103,580$8,628,385.18$19,272$14.05+$11.08MOCSL
10$70,869,433$58,988,602.24$20,631$10.26+$70.85MOCSL

OCSL vs BAX: Complete Analysis 2026

OCSLBDC

Oaktree Specialty Lending Corporation is a business development company specializing in investments in middle market, bridge financing, first and second lien debt financing, unsecured and mezzanine loan, mezzanine debt, senior and junior secured debt, expansions, sponsor-led acquisitions, preferred equity and management buyouts in small and mid-sized companies. It seeks to invest in education services, business services, retail and consumer, healthcare, manufacturing, food and restaurants, construction and engineering, and media and advertising sectors. It invests between $5 million to $75 million principally in the form of one-stop, first lien, and second lien debt investments, which may include an equity co-investment component in companies with enterprise value between $20 million and $150 million and EBITDA between $3 million and $50 million. The fund has a hold size of up to $75 million and may underwrite transactions up to $100 million. It primarily invests in North America. The fund seeks to be a lead investor in its portfolio companies.

Full OCSL Calculator →

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →
📬

Get this OCSL vs BAX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCSL vs SCHDOCSL vs JEPIOCSL vs OOCSL vs KOOCSL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.